Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection
NCT07077798Not yet recruiting
- Start
- Aug 2025
- Primary completion
- Aug 2026
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
Randomised, open-label trial of sintilimab and lenvatinib in hepatocellular carcinoma (HCC) (2 arms). Primary endpoint: Disease-Free Survival up to 60 months. Planned start Aug 2025; status: not yet recruiting.
02
Drugs
sintilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07077798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07077798.